This clinical trial is focused on studying a condition known as hypogonadotropic hypogonadism, which affects hormone production in men. The study will explore the effects of a treatment using a medication called lutropin alfa, also known as human recombinant luteinising hormone. This medication will be compared to another treatment called urinary hCG (Gonasi HP), which is commonly used for this condition.

The purpose of the study is to understand how lutropin alfa affects the body, particularly in terms of increasing testosterone levels, which is a key hormone in men. Participants will receive different doses of lutropin alfa through subcutaneous injections, which means the medication is injected under the skin. The study will monitor how testosterone levels change in response to the treatment and compare these changes to those seen with the standard treatment, urinary hCG.

The study will take place over a period of time, with participants receiving the treatment and having their testosterone levels checked regularly. This will help researchers determine if lutropin alfa could be a more effective treatment option for men with hypogonadotropic hypogonadism or male infertility. The findings from this study could provide valuable insights into new treatment possibilities for these conditions.